RTOG Foundation
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, RTOG Foundation sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
RTOG Foundation: 6 sponsored US clinical trials, 1 recruiting.
RTOG Foundation sponsors 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 1 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Head and Neck Squamous Cell Carcinoma (HNSCC), with 1 trials.
Upper-quartile sponsor footprint
RTOG Foundation sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
NCT06955169
A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery
NCT03809000
SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma
NCT03546582
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
NCT02743078
Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC
NCT02768558
Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer
NCT02764593
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the RTOG Foundation pipeline
1 recruiting of 6 indexed (17% open); 1 completed (17%).
Phase mix: 1 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Head and Neck Squamous Cell Carcinoma (HNSCC) (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
RTOG Foundation: open-pipeline peers nationwide
Peers matched on 6 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
RTOG Foundation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
Related
What to do with this RTOG Foundation page
6 registered trials is a research-attention snapshot, not an endorsement of RTOG Foundation or any single study.
- 1 of RTOG Foundation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Head and Neck Squamous Cell Carcinoma (HNSCC) is the condition RTOG Foundation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Head and Neck Squamous Cell Carcinoma (HNSCC) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. RTOG Foundation pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.